Shares of RAPT Therapeutics Inc. (RAPT), a clinical-stage immunology-based biopharmaceutical company, surged over 60% to $1.39 in premarket trading after announcing an exclusive license agreement with Shanghai Jemincare Pharmaceutical, a subsidiary of Jiangxi Jemincare Group, for JYB1904/RPT904.
RPT904 is a novel, long-acting anti-IgE monoclonal antibody aimed at treating food allergies, chronic spontaneous urticaria (CSU), and other allergic inflammatory diseases.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.